APDW 2026(Asian Pacific Digestive Week)▷ Date : November 26-28, 2026▷ Venue : Manila, Philippines - Philippine International Convention Center (PICC)▷ TaeWoong Booth : #73▷ Website : https://www.apdw2026manila.com/

TaeWoong Medical participated in ENDO 2026September 24-26, 2026Cape Town, South Africa (CTICC - Cape Town International Convention Centre)TaeWoong Medical participated in ENDO 2026, held in Cape Town, South Africa, from September 24 to 26, 2026. During the congress, the company showcased its products and hosted hands-on training sessions featuring HOT SPAXUS™ and EUSRA™, providing healthcare professionals with opportunities to experience the devices and exchange clinical insights.The EUSRA™ hands-on training sessions were led by Prof. Tae-Jun Song and Prof. Dong-Wan Seo of Asan Medical Center, South Korea, and Dr. Zhen Ding of the First Affiliated Hospital of Sun Yat-sen University, Guangzhou, China.The HOT SPAXUS™ hands-on training sessions were conducted by Dr. Didintle Mokgoko of Life Fourways Hospital, South Africa, Prof. Ryan Law of Mayo Clinic, United States, and Dr. Long Rong of Peking University Hospital, China. The exhibition booth also welcomed healthcare professionals from around the world, creating opportunities to discuss clinical practice, share product information, and gather valuable feedback. TaeWoong Medical extends its sincere appreciation to the trainers, healthcare professionals, and visitors who contributed to the event’s success. The company looks forward to continuing these exchanges at future international congresses.

TIPES 2026 has successfully come to a close! Held from September 5–6 at the MOTC International Convention Center in Taiwan, TIPES celebrated its third edition this year.The congress brought together healthcare professionals and medical device companies, providing a valuable platform to exchange medical knowledge, share experiences, and explore advances in medical technology.At TIPES 2026, TaeWoong Medical participated not only with our exhibition booth but also by conducting a hands-on training session featuring EUSRA™.The training was led by Prof. Jae Min Lee from Korea University Anam Hospital, Korea, with the support of Prof. Mu Hsien Lee from Chang Gung Memorial Hospital, Taiwan.It was a meaningful opportunity to introduce EUSRA™ and provide hands-on experience to approximately 20 young doctors, many of whom were experiencing our product for the first time.We sincerely appreciate everyone who visited our booth and participated in the training session, as well as the professors who helped make this valuable educational opportunity possible.We hope to see you again at TIPES!

TaeWoong Medical Obtained ISO 14001 Environmental Certification, Reaffirming Our Commitment to SustainabilityOn July 31, 2026, TaeWoong Medical obtained ISO 14001:2015 certification for environmental management systems. This reflects our ongoing commitment to environmental responsibility across our product development and manufacturing processes. We will continue to pursue sustainable management that balances advanced medical device innovation with eco-friendly practices.

ENDO 2026(5TH WORLD CONGRESS OF GI ENDOSCOPY)▷ Date : September 24-26, 2026▷ Venue : Cape Town, South Africa - Cape Town International Convention Centre (CTICC)▷ TaeWoong Booth : Silver 4▷ Website : https://easternsun.eventsair.com/2026-endo-congress/

CSI FrankfurtJune 3-6, 2026 | Frankfurt, Germany (Forum Messe) At CSI Frankfurt 2026, we had the opportunity to introduce the recent CE Mark approval of PULSTA CE to leading European key opinion leaders (KOLs) who had been eagerly anticipating its commercial launch. The announcement generated significant interest and positive engagement throughout the meeting.Visitors to the exhibition booth were invited to experience the valve loading and deployment process firsthand. Many physicians commented on the intuitive design, highlighting the simplicity, efficiency, and user-friendly nature of the system.A live case was also successfully performed on June 5. The procedure was conducted by Prof. Peter Ewert of the German Heart Center Munich, with Prof. Gi-Beom Kim serving as the proctor. Following CE Mark approval, this represented the first live PULSTA CE case performed and broadcast from a European clinical site, marking an important milestone in the product's introduction to the European market and demonstrating its clinical applicability to an international audience.

TaeWoong Medical Successfully Concludes ESGE 2026May 14-16, 2026Milan, Italy (Allianz MiCo, Milano Convention Centre)TaeWoong Medical successfully concluded its participation in ESGE 2026.ESGE Days, organized by the European Society of Gastrointestinal Endoscopy, is one of Europe’s leading congresses in the field of gastrointestinal endoscopy. Since its first edition in 2018, the event has continued to grow, establishing itself as a key international platform where experts from around the world share the latest insights and clinical experiences in gastrointestinal endoscopy.At ESGE 2026, TaeWoong Medical showcased its broad portfolio of therapeutic endoscopy solutions, including its newly MDR-certified Cystotome, as well as its RFA and Stent product lines. In particular, the company operated Hands-on sessions featuring EUSRA™ and Hot SPAXUS™, providing visitors with the opportunity to experience the usability and clinical value of the products firsthand.Throughout the exhibition, TaeWoong Medical’s booth welcomed physicians and industry professionals from Europe and around the world. Through in-depth discussions and meaningful exchanges of information, the company was able to build valuable networks and further reaffirm its brand recognition and product competitiveness in the global market.Through these activities, the company achieved meaningful outcomes beyond product exhibition, strengthening trust with global partners and expanding opportunities for future collaboration.

TaeWoong Medical at DDW 2026: A New Chapter, Led by TaeWoong USAMay 3-5, 2026McCormick Place Convention Center, West Building, Chicago, IL USA TaeWoong Medical was proud to participate in Digestive Disease Week (DDW) 2026 — and this year's exhibition marked a significant milestone in our global journey. For the first time, TaeWoong USA took the lead as the primary host of our DDW presence, a meaningful shift that reflects our growing commitment to and deepening roots in the U.S. market. What had long been organized and driven by our headquarters in Korea now stands as a testament to the strength and maturity of our U.S. operations. The timing of this transition made the occasion even more momentous. We were proud to announce at DDW 2026 the long-awaited FDA clearance of SPAXUS — a regulatory achievement that our team has pursued with dedication over many years. The opportunity to share this breakthrough news in person, within the heart of the global gastroenterology community, added a layer of significance that the entire TaeWoong team will not soon forget. Visitor engagement at our booth was exceptional throughout the event. Clinicians, procurement professionals, and industry partners from across the world took part in hands-on product demonstrations, experiencing our solutions directly and leaving with a deeper understanding of what TaeWoong brings to therapeutic endoscopy. Product inquiries were abundant, and the quality of conversations reflected the high level of interest our portfolio continues to generate. Our single-use duodenoscope drew considerable attention, underscoring the industry's sustained focus on infection prevention and patient safety. Of equal note was the enthusiastic response to our accessories lineup, which proved to be every bit as compelling as our established stent portfolio. With TaeWoong USA at the forefront, DDW 2026 allowed us to present our most comprehensive and diverse product lineup to date — a reflection of how far we have come and a preview of where we are headed. We extend our heartfelt gratitude to all who visited our booth, participated in demonstrations, and engaged with our team. Your interest and insights are what drive us forward.

ESGE DAYS 2026(European Society of Gastrointestinal Endoscopy)▷ Date : May 14-16, 2026▷ Venue : Milan, Italy (Allianz MiCo, Milano Convention Centre)▷ TaeWoong Booth : #22▷ Website : https://esgedays.org/

TaeWoong Medical Secures CE MDR Class III Certificationin Europe for Pulmonary Valve ‘PULSTA™’TaeWoong Medical Co., Ltd., a specialized medical device company, announced that its self-developed pulmonary valve product, PULSTA™, has obtained certification under the European medical device regulation CE MDR (Medical Device Regulation).On January 30, TaeWoong Medical held a formal certification award ceremony at its headquarters, where it received CE MDR Regulation (EU) 2017/745 certification from the global notified body BSI.The certified product, PULSTA™, is a high-risk implantable medical device used in patients with complex cardiac conditions. By successfully obtaining Class III certification, which is subject to the most stringent evaluation standards in Europe, the product’s clinical effectiveness and safety have been verified in accordance with European regulatory requirements.Compared to the former Medical Device Directive (MDD), CE MDR significantly strengthens requirements for clinical data as well as post-market surveillance (PMS). Despite ongoing certification bottlenecks for high-risk Class III devices across Europe, Taewoong Medical successfully completed the certification process through BSI, demonstrating its strong technological and regulatory capabilities.A representative of Taewoong Medical stated,“The CE MDR certification of PULSTA™ represents an essential gateway not only to the European market but also to other global markets that recognize or align with MDR standards. Through this achievement, we aim to provide safer and more innovative treatment options for patients and clinicians, while aggressively expanding our commercial presence across Europe.”Read the full article

JCIC 2026(Japanese society of Congential Interventional Cardiology)January 22-24, 2026TaeWoong Medical participated in the 2026 JCIC, successfully completing two PULSTA live cases during the congress. These live cases provided an excellent opportunity to highlight the clinical advantages of PULSTA during actual procedures.At the exhibition booth, 3D heart models of the live case patients were prepared, allowing visitors to take part in an immersive hands-on training experience. Participants were able to directly deploy PULSTA into patient-specific heart models, providing a realistic and practical understanding of the procedure and enhancing engagement through experiential learning.TaeWoong Medical was honored to participate in the 2026 JCIC and appreciated the opportunity to engage with clinicians and industry professionals. We would like to express our sincere gratitude to all participants who visited our booth and showed interest in PULSTA. Taewoong Medical remains committed to advancing structural heart solutions and looks forward to continued collaboration with the clinical community.